Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company focused on developing briquilimab, an aglycosylated monoclonal antibody targeting KIT (CD117) for chronic mast cell diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma. The JSPR news feed highlights company announcements on clinical data, corporate developments and financing activities that shape the outlook for this mast cell–focused program.
News updates commonly cover clinical trial results and study updates. Jasper has reported data from the BEACON Phase 1b/2a study in CSU, an open-label extension study in chronic urticarias, and the ETESIAN Phase 1b/2a study in allergic asthma. These releases describe endpoints such as Urticaria Activity Score over 7 days (UAS7), hives and itch severity scores, airway hyperresponsiveness, sputum eosinophils, serum tryptase, and safety findings, including observations related to KIT blockade.
The JSPR news stream also includes corporate and strategic announcements, such as leadership changes, corporate reorganizations, and decisions to concentrate resources on briquilimab in mast cell driven diseases. Investors can find information on Jasper’s participation in healthcare and investor conferences, where management discusses briquilimab’s development and provides program updates.
In addition, Jasper issues financing and capital markets news, including details of public offerings of common stock, pre-funded warrants and common warrants, and stated uses of proceeds for advancing briquilimab and supporting general corporate purposes. Together, these news items provide context on clinical progress, strategic focus and funding for Jasper’s lead program. For readers tracking JSPR, this page offers a centralized view of the company’s press releases and related communications.
Jasper Therapeutics (NASDAQ: JSPR) reported updated clinical data for briquilimab in chronic spontaneous urticaria (CSU) from the randomized BEACON Phase 1b/2a study and an open‑label extension. In the BEACON 240mg→180mg Q8W cohort (briquilimab, n=6) mean UAS7 fell by 31 points at 12 weeks; 83% had UAS7=0 by week 3 and 67% had UAS7=0 at week 12. In the open‑label extension, 58% of CSU patients (n=36) achieved UAS7=0 at 12 weeks and 75% reached UAS7≤6. Median follow‑up was 205 days in 63 patients. Safety findings were infrequent, predominantly low‑grade, and no dose‑limiting toxicities were observed. Jasper said data support dose selection for a Phase 2b CSU study planned for the second half of 2026.
Jasper Therapeutics (Nasdaq: JSPR) named Jeet Mahal as President and Chief Executive Officer and board member, effective Jan 5, 2026, with Thomas Wiggans appointed Executive Chairperson. Jasper is preparing to commence a registrational program for briquilimab in chronic spontaneous urticaria (CSU) and cited proof of concept in CSU, chronic inducible urticaria (CIndU) and asthma. The company will host an investor webinar on Jan 8, 2026 at 8:00 a.m. ET to present updated BEACON study and open-label extension data; slides and a webcast archive will be posted on investor relations.
Jasper Therapeutics (Nasdaq: JSPR) reported positive preliminary Phase 1b ETESIAN results for briquilimab in allergic asthma and closed an internal BEACON investigation. A single 180mg subcutaneous dose produced marked reductions in sputum eosinophils and serum tryptase and improved Early and Late Asthmatic Response (LAR %Max FEV1 +10.4% at 6 weeks, +8.7% at 12 weeks versus baseline). Briquilimab was well tolerated. The BEACON probe found no drug product issues; Jasper concluded the anomalous lack of CSU efficacy in 10 US patients likely reflected patient selection (9 of 10 likely not mast cell-driven). Jasper expects additional BEACON data in Q1 2026 and plans Phase 2b CSU dosing selection mid-2026.
Jasper Therapeutics (NASDAQ:JSPR) will host an investor webinar on Tuesday, December 2, 2025 at 8:00 am ET to present preliminary ETESIAN asthma data and findings from its investigation into anomalous BEACON CSU results reported in July. The session will include remarks from Jasper management and Dr. Martin Metz, M.D., lead EU investigator in BEACON, followed by a live Q&A. Registration is required and presentation slides plus live and archived webcast links will be posted on Jasper's Investor Relations Events page.
Jasper Therapeutics (Nasdaq: JSPR) reported Q3 2025 results and a corporate update on Nov 10, 2025. Key financials: $50.9M cash as of Sept 30, 2025 and a $30M underwritten offering that the company says extends cash runway through H1 2026. Q3 operating items included R&D $14.4M, G&A $4.8M, and a net loss $18.7M (loss per share $1.13).
Clinically, Jasper is investigating anomalous efficacy in two BEACON cohorts (240mg Q8W and 240mg/180mg Q8W) and reports preliminary findings that the anomalies do not appear related to drug substance or drug product. The company plans final investigation conclusions in Q4 2025, initial ETESIAN asthma data in Q4 2025, and additional BEACON/OLE updates in early Q1 2026, aiming to select dose and commence a Phase 2b CSU study mid-2026.
Jasper Therapeutics (Nasdaq: JSPR) announced management will present at four investor conferences in November–December 2025: UBS Global Healthcare (Nov 9–12), Stifel Healthcare (presentation Nov 11, 4:00 PM ET, presentation), TD Cowen Immunology & Inflammation (presentation Nov 12, 3:30 PM ET, fireside chat) and Evercore Healthcare (presentation Dec 3, 3:00 PM ET, fireside chat).
Live webcasts will be available on Jasper's Investor Relations "News & Events – Events" page and archived replays will be posted for 30 days after each live broadcast.
Jasper Therapeutics (NASDAQ:JSPR), a clinical-stage biotech company developing briquilimab for mast cell driven diseases, has announced the pricing of a $30 million public offering. The offering includes 11.67 million shares of common stock and warrants at $2.43 per share, plus 675,000 pre-funded warrants.
The common warrants will have an exercise price of $2.92 per share, exercisable after six months for four years. The proceeds will fund briquilimab's development for conditions including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, along with general corporate expenses. The offering is expected to close around September 22, 2025, with TD Cowen acting as sole book-running manager.
Jasper Therapeutics (Nasdaq: JSPR), a clinical-stage biotech company, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock, pre-funded warrants, and accompanying common warrants. TD Cowen will serve as the sole book-running manager.
The company plans to use the proceeds to advance the development of briquilimab, their novel antibody therapy targeting KIT (CD117). This therapy is being developed for mast cell-driven diseases including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. Additional funds will support general corporate purposes, including capital expenditures and working capital.
Jasper Therapeutics (NASDAQ:JSPR), a clinical stage biotech company, will participate in two major investor conferences in September 2025. The company, which is developing briquilimab, a novel antibody therapy targeting KIT (CD117) for mast cell driven diseases, will present at the Cantor Fitzgerald Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 9.
Both presentations will be in fireside chat format and will be available via webcast on Jasper's Investor Relations website, with replays accessible for 30 days after the events.
Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2025 financial results and provided updates on briquilimab, its novel antibody therapy targeting c-Kit. The company reported strong efficacy data in chronic urticaria trials, with 89% complete response rate in CSU patients across 240mg and 360mg single-dose cohorts, and 92% complete response in CIndU patients in the 180mg SPOTLIGHT cohort.
However, the company is investigating anomalous results in two BEACON study cohorts where 11 of 13 patients showed no UAS7 reduction, potentially due to product lot variability. Jasper implemented a 50% workforce reduction to focus on urticaria programs and reported Q2 financials with $39.5M cash position and a net loss of $26.7M. The planned Phase 2b CSU study is now delayed to mid-2026.
FAQ
What is the current stock price of Jasper Therapeutics (JSPR)?
What is the market cap of Jasper Therapeutics (JSPR)?
